Key Drivers
- Margin Expansion
- Cash Burn
- Share Dilution
AIAI Summary
LEGN's investment case has shifted from speculative biotech to a real commercial scaling story after its first profitable quarter and strong CARVYKTI-driven growth, but the stock still hinges on one product and one partner ecosystem while cash flow remains negative and dilution/execution risk limits how far the rerating can go.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Cash Burn
- •Share Dilution
LEGN showed a strong quarterly turnaround with 65% gross margin, ~15% operating margin, and positive net income, but ongoing negative operating/free cash flow, dilution, and a still-premium valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support rebound
- •High volatility
LEGN has rebounded off the late-July low and improved short-term momentum, but lower highs and overhead resistance in the low-20s keep the broader trend cautious until it can reclaim and hold that area.
Sharp drop into the late-July low near $18.55, followed by volatile swings and a rebound above $20
Sentiment & News
Key News Insights:
- •CARVYKTI Growth
- •First Profitability
- •CEO Transition
Legend Biotech's latest results show strong CARVYKTI-driven growth and its first company-wide profit, though leadership changes and mixed analyst moves may keep sentiment volatile.
The earnings beat and improving profitability support a constructive outlook, but near-term share moves may remain sensitive to leadership and analyst updates
Similar Companies in Healthcare
Other companies in the same sector with AI ratings